
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes is a fully integrated biotechnology company with promising research and development focused on addressing unmet medical needs in therapeutic areas. The company's strong stable of marketed drugs, including Aritstada and Vivitrol, and its profitable base business are expected to generate over $300M in adj. EBITDA this year. Additionally, with ALKS 2680, an OX2R agonist, in Ph 2b studies for NT1/NT2/IH, the company has the potential to grow to over $2B by 2030 in the US, resulting in a positive outlook on the stock.
Bears say
Alkermes is facing positive updates and strong competition in the market for its products, specifically in the sleep disorders market. However, with increased patient numbers and incorporation of a parallel design, their Ph 2 program continues to experience delays which may impact their ability to reach their desired market share and achieve long-term success.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares